FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis

Date: November 30, 2012
Pages: 68
Price:
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FFB3F665953EN
Leaflet:

Download PDF Leaflet

FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis
FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi’s Fluzone and Vaxigrip, GlaxoSmithKline’s Fluarix and FluLaval and Novartis’ Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca’s intranasal FluMist and Sanofi’s Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available. FluBlok is being developed by the Protein Sciences Corporation (PSC), headquartered in Meriden, Connecticut in the US. FluBlok is the leading vaccine candidate in PSC’s vaccine portfolio that also focuses on pandemic influenza, SARS and flu vaccine adjuvants. The trivalent vaccine consists of recombinant hemagglutinin protein, from H1, H3 and B strains, that are propagated in a baculovirus expression vector system in insect cells (FDA Briefing document). The vaccine is a first-in-class product that is the first vaccine to use an insect cell-based manufacturing system in the US.

Scope
  • Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on FluBlok including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for FluBlok in the US from 2011 to 2022.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for seasonal Influenza.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of FluBlok performance
  • Obtain sales forecast for Tabalumab from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis

4 DISEASE MANAGEMENT

4.1 Influenza Vaccination Policy

5 COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment

6 OPPORTUNITY AND UNMET NEED

6.1 Overview
6.2 Unmet Needs
  6.2.1 Higher level of patient awareness
  6.2.2 Increased efficacy in the elderly and young children (<2 years old)
  6.2.3 Improved vaccine side-effect profiles
  6.2.4 More efficient vaccine manufacturing process
  6.2.5 More cost-effective vaccines
6.3 Gap Analysis
6.4 Opportunities
  6.4.1 Expanded breadth of protection against viral strains
  6.4.2 Increased duration of protection
  6.4.3 T-cell involvement

7 PIPELINE ASSESSMENT

7.1 Overview
7.2 Promising vaccines in clinical development
  7.2.1 FluBlok

8 APPENDIX

8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 Forecasting Methodology
  8.4.1 Vaccine Coverage
  8.4.2 Vaccines Included
  8.4.3 Key Launch Dates
  8.4.4 Influenza Vaccine Tender System Assumptions
  8.4.5 General Pricing Assumptions
  8.4.6 Pricing of Pipeline Agents
8.5 Physicians and Specialists Included in this Study
8.6 Primary Research - Prescriber Survey
8.7 About the Authors
  8.7.1 Authors
  8.7.2 Epidemiologists
  8.7.3 Global Head of Healthcare
8.8 About GlobalData
8.9 Contact Us
8.10 Disclaimer

LIST OF TABLES

Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Overall Unmet Needs - Current Level of Attainment
Table 7: Clinical Unmet Needs - Gap Analysis, 2012
Table 8: Seasonal Influenza Vaccines - Phase Pipeline, 2012
Table 9: Product Profile - FluBlok
Table 10: FluBlok SWOT Analysis, 2012
Table 11: Global Sales Forecasts ($m) for FluBlok, 2012-2022
Table 12: Key Launch Dates
Table 13: Physicians Surveyed, By Country

LIST OF FIGURES

Figure 1: Influenza Virus Structure
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022

Ask Your Question

FluBlok (Seasonal Influenza Vaccines) Forecast and Market Analysis
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: